Keyphrases
Temozolomide
100%
Topotecan
100%
Refractory Neuroblastoma
100%
Bevacizumab
100%
Neuroblastoma
100%
Irinotecan
100%
Progression-free Survival
66%
High-risk Neuroblastoma
50%
Random Assignment
33%
Response Criteria
16%
Organ Function
16%
Phase II Trial
16%
Response Evaluation Criteria in Solid Tumors (RECIST)
16%
Performance Status
16%
Overall Survival
16%
Overall Survival Time
16%
Success Criteria
16%
Chemotherapy Regimen
16%
Antitumor Activity
16%
Risk Ratio
16%
Chemoimmunotherapy
16%
Best Overall Response
16%
Function Status
16%
32 Factorial Design
16%
Tolerability
16%
EudraCT
16%
Potential Interaction
16%
Adjusted Hazard Ratio
16%
Antiangiogenic Agents
16%
Survival Estimation
16%
Medicine and Dentistry
Topotecan
100%
Bevacizumab
100%
Temozolomide
100%
Irinotecan
100%
Ganglioneuroblastoma
100%
Progression Free Survival
57%
Overall Survival
28%
Angiogenesis Inhibitor
14%
Phase II Trials
14%
Survival Estimate
14%
Antineoplastic Activity
14%
Chemoimmunotherapy
14%
Hazard Ratio
14%
Arm
14%
Survival Time
14%
Chemotherapy
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Topotecan
100%
Neuroblastoma
100%
Temozolomide
100%
Bevacizumab
100%
Irinotecan
100%
Progression Free Survival
57%
Overall Survival
28%
Tolerability
14%
Antitumor Activity
14%
Phase II Trials
14%
Survival Time
14%
Angiogenesis Inhibitor
14%
Chemotherapy
14%
Diseases
14%